Boston, United States
Nimbus Therapeutics, founded in 2009, is a pioneering biotechnology company headquartered in the United States. The company is dedicated to developing breakthrough medicines through precision small molecule design, leveraging sophisticated computational technologies and machine learning-based predictive modeling to target difficult-to-drug areas.
Nimbus stands out in the health care and biotechnology sector for its focus on structure-based drug discovery tailored to tackle multiple human diseases. Notably, the company's pipeline includes a clinical-stage HPK1 inhibitor for cancer treatment (NCT05128487) and an innovative portfolio targeting cancer, autoimmune conditions, and metabolic disorders.
The company recently secured a significant $210.00 million in a Private Equity Round on 06 September 2023, backed by reputable investors such as Atlas Venture, GV, Lightstone Ventures, RA Capital Management, SV Health Investors, BVF Partners, SR One, Pfizer Venture Investments, Gates Frontier Fund, and Bain Capital Life Sciences. This substantial funding underscores investor confidence in Nimbus' cutting-edge approach and strategic vision.
RAPT Therapeutics